Results 211 to 220 of about 77,580 (287)

Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT We report a 69‐year‐old man diagnosed as myelodysplastic syndrome and administrated with azacitidine and selinexor treatment. Then he was revealed high fever and multiple tender erythematous papules involving his mouth, back, upper and lower extremities, which were diagnosed as Sweet's syndrome by skin biopsy.
Liya Ma, Yaojia Shen, Jie Chang, Shanshan Suo, Lu Wang, Weifang Zhu, Jianjun Qiao, Hongyan Tong   +7 more
wiley   +1 more source

Comparing Different As‐Treated Approaches: A Methodological Study Using Real‐World Data on Psoriasis Treatments

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 2, February 2026.
ABSTRACT Background Accurate pharmaco‐epidemiological assessment of the safety of biological treatments is essential but methodologically challenging. Aims This study evaluated how different assumptions regarding treatment switching and treatment episode definitions affect outcome estimates in psoriasis patients, focusing on malignancies and serious ...
Sejun Kim, Andreas Jensen, Alexander Egeberg, Lone Graff Stensballe   +3 more
wiley   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Single‐Cell Genetic Mapping of Gasdermin Expression Across Immune‐Mediated Inflammatory Diseases

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
This figure illustrates the lineage‐specific causal effects of gasdermin (GSDM) expression on the risk of eight immune‐mediated inflammatory diseases (IMIDs). The analysis, based on single‐cell genetic data, shows how GSDMA, GSDMB, and GSDMD affect disease risk in various immune cell types, highlighting distinct protective or risk‐enhancing roles in ...
Xin Gao, Xiaofeng Guo, Kaige Yin, Xiaoxu Jin   +3 more
wiley   +1 more source

Longitudinal Relationship Between Pain and Depression in People With Inflammatory Arthritis: A Narrative Review

Arthritis Care &Research, Volume 78, Issue 1, Page 15-30, January 2026.
As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox, Saeed Farooq, Helen Twohig, Ian C. Scott   +3 more
wiley   +1 more source

Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis

Arthritis Care &Research, Volume 78, Issue 1, Page 154-163, January 2026.
Objective Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early ...
Zoe Rutter‐Locher, Sam Norton, Joseph L. Taylor, Bina Menon, Tom Esterine, Ruth Williams, Leonie S. Taams, Kirsty Bannister, Bruce W. Kirkham   +8 more
wiley   +1 more source

Beyond Inflammation: Why Understanding the Brain Matters in Inflammatory Arthritis

Arthritis Care &Research, Volume 78, Issue 1, Page 3-14, January 2026.
Persistent pain remains a major challenge in inflammatory arthritis, even when joint inflammation is well controlled. Pain and associated symptoms such as fatigue cannot be explained by peripheral inflammation alone but reflect altered central pain processing. These changes may arise through “top‐down” mechanisms, reflecting pre‐existing dysfunction in
Eoin M. Kelleher, Rosario Meouchi, Anushka Irani   +2 more
wiley   +1 more source

Lymphocyte Activation Gene 3 Regulation of Profibrotic Cytokines and Type I Collagen Production in Patients With Systemic Sclerosis

ACR Open Rheumatology, Volume 8, Issue 1, January 2026.
Objective Diffuse cutaneous systemic sclerosis (dcSSc) is characterized by skin and internal organ fibrosis. The regulatory aspects of the immune system involved in maintaining tolerance are still poorly understood in dcSSc. The late checkpoint inhibitory lymphocyte activation gene 3 (LAG‐3) is implicated in T cell inhibition by interacting with its ...
Maithri Aspari, Stinne Greisen, Malene Hvid, Voon H. Ong, Christopher P. Denton, David Abraham, Bent Deleuran   +6 more
wiley   +1 more source

Similar Pain Scores in Rheumatoid Arthritis and Osteoarthritis Over 45 Years Despite Dramatically Fewer Swollen Joints in Rheumatoid Arthritis: Are Scores Based as Much on Pain Sensitization and Patient Distress as on Inflammation and/or Structural Damage?

ACR Open Rheumatology, Volume 8, Issue 1, January 2026.
This narrative review presents five observations concerning 0 to 10 pain Visual Analog Scale (VAS)/Visual Numeric Scale (VNS) scores in routine care patients with primary diagnoses of rheumatoid arthritis (RA) or osteoarthritis (OA) over more than four decades: (1) Although median RA swollen joint counts declined from 12 of 28 in 1985 to 0 of 28 in two
Juan Schmukler, Tengfei Li, Joel A. Block, Theodore Pincus   +3 more
wiley   +1 more source